Category: SeaPRwire

SmartFollow adalah platform bantuan investasi profesional yang dirancang khusus untuk para investor, berkomitmen membantu pengguna dengan mudah menjelajahi peluang pasar global, mengikuti mentor pakar berpengalaman secara real-time, serta melalui analisis data cerdas membuat keputusan keuangan yang lebih rasional dan lebih efisien. Setelah pengujian ketat pada tahap uji coba publik dan pengasahan mendalam berdasarkan umpan balik autentik dari banyak pengguna, SmartFollow versi resmi (V1.0) akhirnya resmi diluncurkan! Upgrade bersejarah ini tidak hanya menandai perubahan elegan platform dari pengujian Beta menjadi produk komersial yang matang, tetapi juga membawa pengalaman stabil, profesional, dan cerdas yang belum pernah ada sebelumnya bagi jutaan investor. Apakah Anda seorang pemula yang baru memasuki dunia investasi, atau seorang pemain berpengalaman yang sudah bertahun-tahun bergulat di pasar, SmartFollow dapat menjadi mitra investasi yang andal bagi Anda. Melalui push data pasar real-time, sistem mengikuti mentor cerdas, mekanisme pelacakan hasil transparan serta antarmuka operasi yang ramah pengguna, SmartFollow membuat pasar yang kompleks menjadi mudah dijangkau, memungkinkan setiap pengguna untuk maju dengan percaya diri di dunia keuangan yang penuh gejolak. Peningkatan Fungsional Inti Secara Menyeluruh Versi resmi telah mencapai lompatan kualitas di berbagai dimensi, jauh melampaui performa versi uji coba, membuat pengguna benar-benar merasakan daya tarik bantuan investasi "tingkat profesional": Rekonstruksi mendalam modul fungsi: Alat inti seperti mengikuti mentor, push sinyal cerdas, analisis portofolio aset, peringatan risiko dan lainnya semuanya dioptimalkan dan ditingkatkan, dengan kecepatan respons yang lebih cepat, akurasi data yang lebih tinggi, memastikan setiap keputusan didasarkan pada wawasan pasar terkini. Peningkatan stabilitas sistem secara signifikan: Setelah beberapa putaran pengujian stres dan optimalisasi arsitektur, bahkan selama periode puncak perdagangan atau peristiwa pasar besar, platform tetap mempertahankan pengalaman lancar ekstrem tanpa lag dan tanpa crash, memungkinkan Anda fokus pada investasi dengan tenang tanpa khawatir masalah teknis. Pemolesan antarmuka operasi yang ekstrem: Desain UI/UX baru yang lebih sederhana dan intuitif, pengguna pemula hanya butuh beberapa menit untuk menguasai; optimalisasi detail seperti dasbor kustom, mode gelap, dukungan multi-bahasa (termasuk bahasa China, Inggris, Indonesia, dll.) membuat setiap kali membuka App menjadi pengalaman yang menyenangkan. Pembukaan bertahap lebih banyak fungsi lanjutan: Setelah versi resmi diluncurkan, kami akan membuka secara bertahap fungsi eksklusif, seperti generasi strategi bantuan AI, area interaksi mentor komunitas, langganan laporan investasi personalisasi, pemantauan aset lintas pasar dengan satu klik dan konten mengejutkan lainnya, terus menciptakan nilai jangka panjang bagi pengguna. Peningkatan ini bukan sekadar penumpukan sederhana, melainkan iterasi presisi berdasarkan ribuan umpan balik pengguna selama periode uji coba. Kami sangat memahami bahwa inti dari alat bantu investasi terletak pada "andal + mudah digunakan + visioner", SmartFollow V1.0 justru berevolusi secara menyeluruh berdasarkan hal ini, mengubah proses investasi dari "mengikuti secara pasif" menjadi "cerdas aktif". Versi Uji Coba Akan Segera Dihentikan, Upgrade dan Migrasi Sangat Mendesak Peringatan penting: Seiring dengan peluncuran resmi versi resmi, versi uji coba asli akan secara bertahap menghentikan semua layanan, termasuk sinkronisasi data, push sinyal mentor dan operasi akun. Untuk menghindari gangguan pada ritme investasi Anda, silakan segera bertindak untuk menyelesaikan upgrade! Jalur upgrade jelas dan mudah: Langsung cari “SmartFollow V1.0” di toko aplikasi atau di dalam App, unduh dan instal versi resmi terbaru. Jika mengalami kesulitan unduh, instalasi atau migrasi data (misalnya catatan transaksi historis, daftar mentor yang diikuti, transfer pengaturan preferensi), Anda dapat kapan saja menghubungi tim dukungan melalui saluran layanan pelanggan bawaan App atau email resmi/obrolan online, kami menyediakan layanan panduan satu lawan satu dan tangan demi tangan, memastikan migrasi 100% mulus. Disarankan untuk mencadangkan data penting sebelum upgrade, dan melakukan operasi di lingkungan jaringan yang stabil, seluruh proses biasanya hanya membutuhkan 5-10 menit. Upgrade sedini mungkin tidak hanya dapat membuka kunci semua fungsi baru dan pengalaman optimalisasi pertama kali, tetapi juga menghindari ketidaknyamanan apa pun setelah versi uji coba dihentikan. Tim SmartFollow telah mempersiapkan dengan baik, mendampingi setiap pengguna untuk transisi lancar ke era baru yang lebih kuat! Mekanisme Keamanan Akun Ditingkatkan Secara Menyeluruh, Perlindungan Aset Tanpa Toleransi Risiko Di bidang keuangan, keamanan selalu menjadi yang utama. Versi resmi telah sangat meningkatkan standar perlindungan keamanan platform, membangun sistem pertahanan stereoskopik multi-lapis, membuat dana dan informasi pribadi Anda sekuat baja: Pendaftaran/login melalui email sepenuhnya diwajibkan: Meninggalkan risiko potensial verifikasi nomor ponsel tradisional, menggunakan sistem email yang lebih aman, mendukung penyedia email mainstream, dan mengintegrasikan deteksi anti-phishing. Mekanisme kata sandi pengisian dana/transaksi independen: Operasi dana sepenuhnya terpisah dari login harian, bahkan jika akun diretas pun sulit untuk langsung mentransfer aset. Enkripsi seluruh rantai dan audit kepatuhan: Semua transmisi data menggunakan enkripsi end-to-end, platform secara berkala menerima audit keamanan pihak ketiga, memastikan sesuai dengan standar perlindungan data keuangan internasional. Kami sangat menyerukan setiap pengguna segera menyelesaikan semua pengaturan keamanan sesuai petunjuk pop-up setelah pertama kali login ke versi resmi. Hanya dengan cara ini, Anda dapat menikmati tingkat perlindungan aset tertinggi yang disediakan platform. Keamanan Anda adalah komitmen abadi kami. Penciptaan Bersama Pengguna dan Balasan Terima Kasih, Umpan Balik Anda Tak Ternilai SmartFollow tidak pernah lupa: Setiap kemajuan platform berasal dari pendampingan tulus dan opini berharga setiap pengguna. Selama periode uji coba, ribuan pengguna penguji dengan antusias mengirimkan laporan bug, saran fungsi, dan berbagi pengalaman pengguna, justru suara autentik ini yang mendorong kami untuk iterasi cepat dan terus menyempurnakan. Setelah versi resmi diluncurkan, kami terus menempatkan "penciptaan bersama pengguna" di posisi utama: Jika menemukan masalah apa pun, ruang optimalisasi atau ide fungsi baru selama penggunaan, silakan langsung kirimkan melalui entri “Umpan Balik” di dalam App atau layanan pelanggan. Semua pengguna yang memberikan umpan balik efektif (termasuk saran perbaikan bug, proposal peningkatan pengalaman, dll.), semuanya dapat memperoleh hadiah balasan eksklusif: seperti perpanjangan masa keanggotaan, laporan mendalam pasar eksklusif, kode pengalaman fungsi lanjutan waktu terbatas, hak tukar poin dan kejutan kesejahteraan lainnya. Setiap umpan balik Anda akan dicatat dengan serius, dievaluasi, dan diprioritaskan untuk diimplementasikan dalam versi selanjutnya. Terima kasih kepada setiap rekan seperjalanan! Justru karena ada Anda, SmartFollow dapat tumbuh dari sebuah ide menjadi mitra investasi profesional saat ini. Di masa depan, kami akan terus mendengarkan, terus berevolusi, dan bersama Anda menulis cerita investasi yang lebih indah. Peluncuran versi resmi SmartFollow hanyalah titik awal dari perjalanan baru yang sepenuhnya. Melihat ke depan, platform akan memperkenalkan lebih banyak alat cerdas yang didorong AI, cakupan pasar global yang lebih luas, ekosistem mentor yang lebih kaya, perencanaan jalur investasi yang lebih personal... segalanya, hanya untuk membuat setiap pengguna berjalan lebih stabil, lebih jauh, dan lebih tenang di jalan investasi. Sekali lagi terima kasih atas kepercayaan dan dukungan Anda! SmartFollow, bersama Anda, maju dengan mantap, menang cerdas di masa depan.

VANCOUVER, BC– 12/03/2026 – (SeaPRwire) – A newly formed digital infrastructure platform has emerged at the intersection of artificial intelligence, tokenized assets, and climate-focused financial systems. The Tomorrow Company (“TMRW”) announced that it has completed a strategic merger with Carbon Distributed Technologies AG (“CUT”) and Plato Technologies Inc., bringing together complementary technologies aimed at building scalable Web3 infrastructure for the next phase of digital finance. The newly combined organization is designed around the premise that long-term value in digital markets will increasingly be created by the builders of foundational systems rather than by application-level interfaces. By focusing on programmable infrastructure, embedded intelligence, and verifiable digital assets, the platform aims to support institutions navigating a rapidly evolving financial and technological landscape. Responding to Structural Shifts in Global Markets Global capital markets are undergoing significant transformation as artificial intelligence, digital assets, and climate accountability frameworks reshape financial operations. AI technologies are increasingly embedded in enterprise decision-making, regulatory compliance, and capital allocation processes. At the same time, blockchain-based assets are evolving beyond speculative instruments toward programmable frameworks capable of enabling transparent, real-time value transfer. Parallel to these developments, climate accountability is also transitioning from voluntary reporting toward measurable, verifiable systems. Regulators, corporations, and institutional investors are increasingly seeking tools that can track environmental impact through auditable mechanisms rather than narrative-based commitments. TMRW’s newly formed platform is designed to operate at the convergence of these emerging trends. Tokenized Carbon Infrastructure from CUT As part of the merger, Carbon Distributed Technologies AG contributes a tokenized carbon infrastructure framework designed to provide transparency and traceability for carbon credits. The system emphasizes verifiable issuance, transfer tracking, and retirement mechanisms intended to ensure that environmental claims can be independently validated. Built within Liechtenstein’s Blockchain Act regulatory framework and operating on the Ethereum mainnet, the CUT platform seeks to establish auditable records for carbon-related transactions while linking tokenized assets to measurable CO₂ reduction outcomes. Paul Thomson, Co-Founder of Carbon Distributed Technologies AG, said the development of tokenized commodities is moving toward greater operational rigor and transparency. According to Thomson, the credibility of tokenized carbon credits increasingly depends on clear verification processes, reliable asset traceability, and robust retirement protocols that can withstand institutional scrutiny. By integrating with TMRW’s broader infrastructure platform, the company expects to accelerate the adoption of programmable carbon market systems. AI Intelligence Layer from Plato Technologies Complementing the carbon infrastructure is Plato Technologies Inc., which contributes an artificial intelligence engine designed to convert fragmented global datasets into operational workflows and actionable insights. The platform focuses on vertically specialized intelligence products intended for enterprise deployment. These systems aim to help organizations convert large volumes of data into decision-ready analytics while maintaining operational scalability and efficiency. Bryan Feinberg, CEO and Founder of Plato Technologies Inc., noted that the true impact of AI emerges when insights are integrated directly into operational systems rather than remaining as analytical outputs. The merger, he said, enables AI capabilities to connect with measurable asset frameworks and distribution-driven infrastructure capable of operating at global scale. A Multi-Engine Web3 Infrastructure Platform Following the merger, The Tomorrow Company will operate as a diversified Web3 infrastructure holding platform. The company’s strategy centers on building multiple interconnected value engines across tokenized assets, AI-driven intelligence systems, and programmable financial infrastructure. Beyond tokenized carbon credits, the company intends to expand its tokenization framework into additional real-world asset categories where digital verification and programmability can unlock liquidity and transparency. Management also plans to scale the deployment of vertical AI intelligence products in industries where fragmented data environments create operational inefficiencies. Strategic acquisitions and technology integrations are expected to play a role in the company’s growth roadmap, particularly where opportunities align with regulatory frameworks, institutional adoption, and long-term infrastructure utility. Positioning for the AI-Native Financial Era Leadership at TMRW believes that the intersection of artificial intelligence and tokenized financial systems will reshape how capital is raised, distributed, and monitored. As financial markets increasingly emphasize transparency and automation, platforms capable of embedding intelligence and programmable accountability into infrastructure may play a growing role in digital economies. The company’s long-term objective is to build a portfolio of infrastructure assets that generate value through adoption and integration rather than short-term market volatility. Its roadmap includes expanding institutional partnerships, strengthening blockchain infrastructure capabilities, and deploying AI systems designed to integrate directly into enterprise and financial workflows. As global markets continue to evolve toward tokenized real-world assets and AI-enabled financial ecosystems, The Tomorrow Company aims to establish itself as a foundational infrastructure layer supporting new digital asset classes and data-driven capital flows. About The Tomorrow Company The Tomorrow Company is a Web3 infrastructure and digital asset holding platform focused on building foundational systems for the emerging AI-driven financial ecosystem. Through acquisitions, tokenized utility frameworks, and vertically deployable AI intelligence products, the company seeks to develop scalable infrastructure designed for institutional adoption and long-term growth. About Carbon Distributed Technologies AG Carbon Distributed Technologies AG operates CUT.eco, a tokenized carbon utility platform designed to provide verification, traceability, and transparent retirement mechanisms for carbon credits under Liechtenstein’s blockchain regulatory framework. About Plato Technologies Inc. Plato Technologies Inc. develops AI-powered intelligence platforms that transform large-scale global datasets into operational workflows and scalable Web3 analytics capabilities. Forward-Looking Statements This press release contains forward-looking statements regarding anticipated strategic initiatives, growth plans, market opportunities, and future performance. These statements are based on current expectations and involve risks and uncertainties that may cause actual outcomes to differ materially from those expressed or implied. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

VANCOUVER, BC– 12/03/2026 – (SeaPRwire) – A newly formed digital infrastructure platform has emerged at the intersection of artificial intelligence, tokenized assets, and climate-focused financial systems. The Tomorrow Company (“TMRW”) announced that it has completed a strategic merger with Carbon Distributed Technologies AG (“CUT”) and Plato Technologies Inc., bringing together complementary technologies aimed at building scalable Web3 infrastructure for the next phase of digital finance. The newly combined organization is designed around the premise that long-term value in digital markets will increasingly be created by the builders of foundational systems rather than by application-level interfaces. By focusing on programmable infrastructure, embedded intelligence, and verifiable digital assets, the platform aims to support institutions navigating a rapidly evolving financial and technological landscape. Responding to Structural Shifts in Global Markets Global capital markets are undergoing significant transformation as artificial intelligence, digital assets, and climate accountability frameworks reshape financial operations. AI technologies are increasingly embedded in enterprise decision-making, regulatory compliance, and capital allocation processes. At the same time, blockchain-based assets are evolving beyond speculative instruments toward programmable frameworks capable of enabling transparent, real-time value transfer. Parallel to these developments, climate accountability is also transitioning from voluntary reporting toward measurable, verifiable systems. Regulators, corporations, and institutional investors are increasingly seeking tools that can track environmental impact through auditable mechanisms rather than narrative-based commitments. TMRW’s newly formed platform is designed to operate at the convergence of these emerging trends. Tokenized Carbon Infrastructure from CUT As part of the merger, Carbon Distributed Technologies AG contributes a tokenized carbon infrastructure framework designed to provide transparency and traceability for carbon credits. The system emphasizes verifiable issuance, transfer tracking, and retirement mechanisms intended to ensure that environmental claims can be independently validated. Built within Liechtenstein’s Blockchain Act regulatory framework and operating on the Ethereum mainnet, the CUT platform seeks to establish auditable records for carbon-related transactions while linking tokenized assets to measurable CO₂ reduction outcomes. Paul Thomson, Co-Founder of Carbon Distributed Technologies AG, said the development of tokenized commodities is moving toward greater operational rigor and transparency. According to Thomson, the credibility of tokenized carbon credits increasingly depends on clear verification processes, reliable asset traceability, and robust retirement protocols that can withstand institutional scrutiny. By integrating with TMRW’s broader infrastructure platform, the company expects to accelerate the adoption of programmable carbon market systems. AI Intelligence Layer from Plato Technologies Complementing the carbon infrastructure is Plato Technologies Inc., which contributes an artificial intelligence engine designed to convert fragmented global datasets into operational workflows and actionable insights. The platform focuses on vertically specialized intelligence products intended for enterprise deployment. These systems aim to help organizations convert large volumes of data into decision-ready analytics while maintaining operational scalability and efficiency. Bryan Feinberg, CEO and Founder of Plato Technologies Inc., noted that the true impact of AI emerges when insights are integrated directly into operational systems rather than remaining as analytical outputs. The merger, he said, enables AI capabilities to connect with measurable asset frameworks and distribution-driven infrastructure capable of operating at global scale. A Multi-Engine Web3 Infrastructure Platform Following the merger, The Tomorrow Company will operate as a diversified Web3 infrastructure holding platform. The company’s strategy centers on building multiple interconnected value engines across tokenized assets, AI-driven intelligence systems, and programmable financial infrastructure. Beyond tokenized carbon credits, the company intends to expand its tokenization framework into additional real-world asset categories where digital verification and programmability can unlock liquidity and transparency. Management also plans to scale the deployment of vertical AI intelligence products in industries where fragmented data environments create operational inefficiencies. Strategic acquisitions and technology integrations are expected to play a role in the company’s growth roadmap, particularly where opportunities align with regulatory frameworks, institutional adoption, and long-term infrastructure utility. Positioning for the AI-Native Financial Era Leadership at TMRW believes that the intersection of artificial intelligence and tokenized financial systems will reshape how capital is raised, distributed, and monitored. As financial markets increasingly emphasize transparency and automation, platforms capable of embedding intelligence and programmable accountability into infrastructure may play a growing role in digital economies. The company’s long-term objective is to build a portfolio of infrastructure assets that generate value through adoption and integration rather than short-term market volatility. Its roadmap includes expanding institutional partnerships, strengthening blockchain infrastructure capabilities, and deploying AI systems designed to integrate directly into enterprise and financial workflows. As global markets continue to evolve toward tokenized real-world assets and AI-enabled financial ecosystems, The Tomorrow Company aims to establish itself as a foundational infrastructure layer supporting new digital asset classes and data-driven capital flows. About The Tomorrow Company The Tomorrow Company is a Web3 infrastructure and digital asset holding platform focused on building foundational systems for the emerging AI-driven financial ecosystem. Through acquisitions, tokenized utility frameworks, and vertically deployable AI intelligence products, the company seeks to develop scalable infrastructure designed for institutional adoption and long-term growth. About Carbon Distributed Technologies AG Carbon Distributed Technologies AG operates CUT.eco, a tokenized carbon utility platform designed to provide verification, traceability, and transparent retirement mechanisms for carbon credits under Liechtenstein’s blockchain regulatory framework. About Plato Technologies Inc. Plato Technologies Inc. develops AI-powered intelligence platforms that transform large-scale global datasets into operational workflows and scalable Web3 analytics capabilities. Forward-Looking Statements This press release contains forward-looking statements regarding anticipated strategic initiatives, growth plans, market opportunities, and future performance. These statements are based on current expectations and involve risks and uncertainties that may cause actual outcomes to differ materially from those expressed or implied. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

BASSETERRE, KN – 10/03/2026 – (SeaPRwire) – As digital assets, traditional banking services, and global payment networks continue to evolve independently, individuals and businesses that operate internationally often face a fragmented financial landscape. Addressing this challenge, the VALYGO platform has officially launched, introducing a unified financial environment designed to consolidate multiple financial functions into a single operational framework. Modern financial activity frequently requires users to rely on separate systems for cryptocurrency management, fiat transactions, payment processing, and cross-border transfers. This fragmentation can slow financial operations, create administrative complexity, and increase operational friction for professionals and companies conducting business across multiple jurisdictions. VALYGO enters this space with the goal of simplifying financial workflows by bringing these capabilities together within one structured platform. A Platform Designed Around Real Financial Workflows Rather than focusing on a single financial service, VALYGO has been designed around the way individuals and businesses interact with money in real-world scenarios. The platform enables users to operate within a connected account environment where several financial functions can coexist and interact. Through the platform, users are able to manage digital assets alongside supported fiat services, conduct card-based transactions both online and at physical merchants, and execute cross-border transfers without relying on multiple external systems. In addition, supported ATM access provides another method for interacting with funds. By integrating these services into one platform environment, VALYGO aims to reduce the need for users to shift between different tools and platforms, helping create greater continuity in everyday financial activity. Supporting Cross-Border Financial Participants The platform has been developed with internationally active users in mind. Freelancers who invoice clients abroad, remote professionals earning income from multiple regions, and businesses maintaining relationships with clients across different countries often require financial infrastructure capable of supporting complex payment flows. VALYGO’s structure seeks to address these needs by providing an operational environment where payments, asset management, and account access can function within a single system. Individuals who frequently interact with both cryptocurrency and traditional financial services may also find value in the platform’s integrated structure. Flexible Account Models for Different Operational Needs Recognizing that users operate at varying scales, VALYGO offers multiple account tiers designed to accommodate different levels of financial activity. This structured approach allows participants to select an account model aligned with their operational requirements. Entry-level access is available for users with more basic needs, while higher-tier accounts provide expanded functionality and may involve participation through the VYO ecosystem component. By offering tiered access, the platform seeks to provide scalability without imposing identical requirements on all participants. VYO Utility Within the Platform Ecosystem Within the VALYGO ecosystem, VYO functions as a utility component connected to platform participation. Its use cases include enabling access to certain account tiers, supporting staking participation, and linking token utility with platform functionality. Rather than existing independently from the platform environment, VYO is designed to operate as part of the broader ecosystem infrastructure, aligning user participation with the system’s operational structure. Transitioning from Development to Active Use With the platform now live, users are able to engage with VALYGO under real operating conditions. The launch represents the transition from development and system design to practical usage. While future updates and improvements may continue as the platform evolves, the current release establishes the foundation for users to interact with a financial environment that brings together digital assets, payment tools, and supported fiat services within a single operational framework. A Unified Operational Layer for Modern Finance VALYGO does not position itself as a traditional bank replacement, a trading platform, or solely a cryptocurrency wallet. Instead, it presents itself as an integrated operational layer intended to connect several financial functions—ranging from crypto access and supported fiat services to payment infrastructure and account management—within one unified environment.

PALO ALTO, CA – 14/03/2026 – (SeaPRwire) – Clockwork.io has announced the general availability of TorchPass Workload Fault Tolerance, a new capability designed to improve resilience in large-scale artificial intelligence training environments. The software-based solution aims to reduce the operational disruption and financial losses associated with infrastructure failures in distributed GPU clusters. TorchPass is delivered as a core feature within the Clockwork.io FleetIQ platform. The technology applies the company’s Software-Driven AI Fabrics architecture to distributed training workloads, enabling systems to continue operating even when GPU hardware, network links, or cluster nodes encounter failures. By leveraging Live GPU Migration, the platform can transparently shift active training workloads to available resources without requiring job restarts or checkpoint recovery. According to Suresh Vasudevan, the cost of infrastructure interruptions has become a growing challenge for organizations investing heavily in AI computing resources. “Companies are investing billions in next-generation accelerators, yet distributed AI workloads still lose significant productivity due to avoidable infrastructure faults,” Vasudevan said. “TorchPass was designed to address that gap by allowing training workloads to continue operating through failures rather than forcing expensive restarts.” Industry observers have also noted that reliability becomes increasingly difficult as AI clusters scale. Dylan Patel said that maintaining continuity across large GPU deployments is becoming critical as new hardware architectures increase cluster density. “As systems scale to larger compute domains, even minor errors—such as a single GPU failure or a network disruption—can terminate an entire training run,” Patel said. “Technologies like TorchPass help maintain utilization by enabling transparent failover and live workload migration.” Addressing Reliability Challenges in Distributed AI Training Distributed AI training is widely recognized as one of the most complex and failure-prone workloads in modern computing infrastructure. Research conducted by Meta FAIR indicates that the mean time to failure decreases sharply as cluster sizes increase. In clusters with more than a thousand GPUs, interruptions can occur within hours, frequently forcing jobs to restart from checkpoints. These interruptions often result in lost compute time and reduced GPU utilization. When failures occur, training systems typically roll back to the latest saved checkpoint, discarding recent progress and requiring additional time to restore workloads. TorchPass is designed to mitigate these inefficiencies by addressing faults proactively and maintaining workload continuity. By reducing restart events and preserving training progress, the system aims to improve cluster utilization and reduce operational overhead for enterprises and AI cloud providers. Live GPU Migration Enables Continuous Training The key mechanism behind TorchPass is Live GPU Migration, which enables affected training processes to move dynamically to spare resources within the cluster when faults occur. The migration process typically completes in approximately three minutes while the overall training workload continues to operate. TorchPass supports three primary resilience scenarios: Unplanned migration, which responds to unexpected failures such as GPU faults, kernel crashes, or power disruptions Pre-emptive migration, triggered by early warning signals including thermal anomalies or ECC memory errors Planned migration, allowing infrastructure maintenance or workload balancing without interrupting training operations According to the company, this approach can reduce wasted training progress by up to 95 percent in certain environments. Independent Testing Highlights Performance Benefits Independent benchmarking conducted by Jordan Nanos evaluated TorchPass in large-scale training scenarios. Testing involved a GPT-scale training workload using a Kubernetes-based cluster equipped with 64 H200 GPUs. The evaluation measured job completion time and model FLOPs utilization against both traditional checkpoint-restart methods and the open-source fault-tolerance framework TorchFT. The results indicated that TorchPass achieved faster recovery after simulated hardware failures while maintaining higher GPU utilization rates. The benchmark also suggested that by improving fault tolerance, organizations may be able to reduce checkpoint frequency in training pipelines. This can enable larger batch sizes, lower memory pressure, and simplified storage management. Financial Impact for Large AI Clusters For operators managing large GPU deployments, improved reliability can translate into significant cost savings. Clockwork.io estimates that in a typical deployment using 2,048 H200 GPUs, TorchPass could recover more than $6 million in annual compute value by preventing wasted GPU hours caused by restart-driven downtime. These savings primarily result from avoiding repeated training interruptions and eliminating idle recovery periods. By maintaining continuous training progress, organizations may also accelerate the time required to complete large model training runs. Supporting Next-Generation AI Infrastructure Clockwork.io positions TorchPass as part of a broader effort to make reliability a software-defined capability within AI infrastructure. This approach is designed to support emerging high-density systems, including architectures built around GPUs such as the NVIDIA GB200 NVL72 and NVIDIA GB300 NVL72. TorchPass expands on the company’s earlier Network Fault Tolerance capabilities, which address network-level disruptions by rerouting traffic around failing links. Together, these technologies form the foundation of Clockwork.io’s Software-Driven AI Fabric, a vendor-neutral software layer designed to coordinate compute, network, and storage resources across large AI clusters. The goal is to enable operators to run heterogeneous infrastructure as a unified system while maintaining predictable performance and high utilization. Clockwork.io will present TorchPass during the upcoming NVIDIA GTC conference from March 16 to 19. About Clockwork.io Clockwork.io develops Software-Driven AI Fabrics, a programmable software layer designed to improve observability, determinism, and fault tolerance in large-scale AI clusters. Its FleetIQ platform enables enterprises to train and operate complex AI workloads while maintaining high infrastructure utilization. Organizations including Uber, Wells Fargo, Nebius, and Nscale use Clockwork.io technologies to support AI infrastructure operations.

On March 18, Hong Kong International Film & TV Market (FILMART) – Asia’s largest film and television trade market-was teeming with activity. Amidst the bustling halls, Huace Group booth drew a diverse international crowd, captivated by the “Oriental scroll” unfolding on screen: the historical Chinese drama Swords into Plowshares, which is currently sweeping the globe. During the market, Huace Group presented a slate of key series including Swords into Plowshares, The Heir, and War and People. The creative team behind Swords into Plowshares also made intensive appearances at several high-profile events. Since its January debut, the series has reached 73 countries and regions in over 11 languages, and becoming a phenomenal start for Chinese content exports in 2026. A Single Series Sparks Tourism in Multiple Cities CEO of Huace Group Invites Viewers: “Travel China with Swords into Plowshares” “I warmly invite global audiences to visit Zhejiang, to recognize the beauty of China appears in Swords into Plowshares, walking the landscapes and feeling China through the series’ poetic imagery and moving stories,” CEO of Huace Group, Fu Binxing said in a keynote address at the “Forum on International Comminication Cooperation and Innovation for a New Vision” on March 17, extending a heartfelt invitation to the show’s global viewers. Set in the same era when Otto I was campaigning in Italy to establish the Holy Roman Empire in the West, China in the East was also mired in the turmoil of the Five Dynasties and Ten Kingdoms. Swords into Plowshares follows three young heroes who meet amid the chaos—Qian Hongshu, Zhao Kuangyin, and Guo Rong—each enduring war and separation, steadfastly fulfilling their duties, presenting a panoramic portrait of war and peace of ancient China. This invitation from the CEO of Huace Group stems from the unprecedented cultural tourism trend sparked by the show. As the drama gained popularity, it triggered a “one show, multiple cities” phenomenon across Zhejiang and the rest of China. Cities featured in the plot, such as Hangzhou, Taizhou, Taiyuan, and Kaifeng, have seen a massive influx of tourists, allowing audiences to step off the screen and into the scenery to experience a thousand-year-old vision of peace. “When Hearts Connect, Stories Resonate” Decoding the Global Success of Swords into Plowshares Since its January premiere, Swords into Plowshares has debuted on over 12 major international platforms, covering 73 countries and regions. On YouTube, it has surpassed 10 million views with total exposure exceeding 100 million, successfully breaking through cultural barriers. The series has also received high industry praise at international festivals in Cannes, Tokyo, and Singapore, marking a successful transition from merely “going abroad” to “going deep” into local markets. Wang Yan, the Producer of Swords into Plowshares, provided an in-depth look at how the series achieved such global resonance. She noted that from the project’s inception, the focus was on international positioning: creating a high-quality, international historical epic. The production utilized 8K standards and ultra-high-definition technology, with a professional cast of over 200 actors meticulously matched to their roles. “Everything was done for one purpose: to allow everyone to have an immersive experience,” she said. “Only when we believe in it and enter that world ourselves can the audience be drawn into the story”. Wang Yan believes that while technology is the shell, the core remains key. The title Swords into Plowshares captures the “soul” of the show, expressing a desire for peace over conflict. This compassion for life and longing for peace are universal human emotions. “Ultimately, international expression isn’t about simplifying history; it’s about excavating the essential, shared emotions of humanity,” Wang Yan said. One overseas viewer commented, “To understand the past is to see the future clearly”. By tapping into these deep layers, cultural barriers are dismantled: “When hearts connect, stories resonate”. Huace Group Releases 2026 Line-up Bringing More Chinese Stories Across the Seas The global journey of Swords into Plowshares is far from over. During this FILMART, Huace Group booth hosted over a hundred meetings with overseas buyers from North America, Japan, South Korea, Singapore, Vietnam, Thailand, and the Philippines. Several international platforms reached new cooperations on-site, further strengthening the global distribution network of Huace Group. The global influence of Swords into Plowshares is part of a broader trend. Huace Group has long pursued a “China Wave” strategy, having distributed nearly 180,000 hours of content to over 200 countries and regions. Its self-operated Huace multi-channel network covers 20 languages with over 58 million overseas subscribers. Other recent global successes include Meet Yourself, which brought the “healing breeze” of Dali to the world; Flourished Peony, which captivated audiences with its exquisite Oriental aesthetics; and contemporary dramas like Go Ahead, which showcase the lives of modern Chinese youth. On the evening of March 18, Huace Group held its “Unound Stories, New Experiences” networking event in Hong Kong, attended by nearly 200 representatives from global media and film institutions. The event featured a heavyweight release of key drama projects, including Swords into Plowshares, The Heir, Sentencing, You are My Fateful Love, Blossom, I Live in Your Time, Now or Never, The Garden of Missing Paths, War and People, and A Simply Jane. Additionally, Huace Group plans to launch over ten mid-to-short-form series such as Zizhi Tongjian and Journey to the West, while actively applying AIGC to explore new paradigms of human-machine collaborative creation. From historical epics to modern realism, and from premium long-form series to innovative content formats, Huace Group is driven by “premium content” and “technological empowerment”. This dual engine is building a new pattern of international communication—moving from “going global” to “going in” and finally “integrating in”. As Fu Binxing stated at the forum: “Huace Group is willing to work with the utmost sincerity to invite global creators, tech companies, platforms, and investors to build a ‘Smart Cultural & Creative Community.’ Let more Chinese stories carrying shared human emotions fly to every corner of the world on the wings of innovative technology”

SINGAPORE – March 18, 2026 – (SeaPRwire) – AdsDrama, a digital platform focused on short drama content and online advertising, has introduced an ecosystem designed to integrate content distribution, advertising services, and user participation. The launch comes as short-form video continues to expand globally, shaping how content is consumed and monetized across digital channels. What Is AdsDrama? AdsDrama (https://www.adsdrama.com) is a platform centered on short drama marketing and digital advertising monetization. It connects content creators, advertisers, and users through a structured system intended to support content distribution and advertising delivery. Unlike traditional content platforms where users primarily consume media, AdsDrama incorporates a participation-based model. Users can engage with certain platform functions related to content promotion and advertising processes. The platform operates through a structured framework designed to simplify user access and participation. User Onboarding New users can register and access an introductory interface that presents the platform’s core features, including its advertising workflows and operational structure. This step is intended to provide a general understanding of how the platform functions. Participation Through Structured Levels After onboarding, users may choose to access different participation levels. Each level provides access to specific platform features, which may include: Defined activity parameters Access to advertising-related tasks System-based allocation of activities The platform indicates that certain processes are managed through internal systems that handle distribution and performance tracking. Automated Advertising System AdsDrama utilizes a data-driven system to distribute short drama content across various digital channels, including: Social media platforms Short video networks Other online content distribution channels The platform states that it applies audience targeting and traffic allocation tools to support content visibility. Revenue Model According to AdsDrama, the platform incorporates multiple revenue streams as part of its business model: Online advertising revenue derived from ad placements and traffic distribution Content monetization, including paid access to selected short drama content Brand collaborations, such as sponsored content and integrations IP commercialization through licensing and content expansion Technology services related to advertising delivery and data optimization The company states that this diversified structure is intended to support ongoing platform development. Key Features of AdsDrama Data-Driven Optimization AdsDrama reports that it uses analytics and performance tracking tools to monitor advertising campaigns and refine delivery strategies. Structured Financial System The platform describes a multi-layer account system designed to manage user balances, which may include: Available balances Processing stages Pending allocations This structure is intended to support internal accounting processes and system organization. Standardized Withdrawal Mechanism AdsDrama indicates that it applies standardized procedures for withdrawals within its operational framework, aiming to streamline processing and reduce administrative complexity. Why AdsDrama Is Growing Industry trends may help explain the emergence of platforms such as AdsDrama: Growth of short-form content, as short video and serialized formats continue to attract broad audiences Expansion of digital advertising, with businesses increasing spending on online channels Gradual shift toward participation-based models, where users engage beyond passive content consumption Is AdsDrama Worth Exploring? AdsDrama may be relevant to individuals and organizations interested in: Digital advertising platforms Content distribution models Emerging forms of online engagement As with any platform, users are encouraged to review publicly available information and consider potential risks before engaging. AdsDrama represents an approach that combines short-form content with digital advertising infrastructure and user-facing features. As the digital media landscape continues to evolve, platforms of this kind reflect ongoing experimentation in content distribution and monetization models. Media contact Brand: AdsDrama LTD Contact: Media team Website: https://www.adsdrama.com

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website: https://www.finharbor.com/

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website: https://www.finharbor.com/

Nicosia, Cyprus – March 17, 2026 – (SeaPRwire) – FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor’s approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client’s internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner’s IBAN account infrastructure. During the second week the team activated card issuing and configured the platform’s connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective “The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. “Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website: https://www.finharbor.com/

The Singapore-headquartered platform helps brands improve content reach and conversion in the era of short-form video and interest-based e-commerce. SINGAPORE – March 16, 2026 – (SeaPRwire) – As short-form video continues to reshape how information spreads and how consumers engage with brands, efficient collaboration between brands and creators has become increasingly important. Hello IP was built to address this need. Hello IP is a content distribution platform focused on social and interest-based e-commerce. By enabling brands to upload ready-made video content and distribute it through local creators across social platforms, Hello IP helps reduce the complexity of traditional creator collaborations, improve campaign efficiency, and create more sustainable monetization opportunities for creators. Under traditional creator marketing models, brands often face lengthy workflows that include influencer sourcing, repeated negotiation, contract signing, sample shipping, content review, and payment settlement. These processes can be slow, costly, and difficult to manage, especially in cross-border campaigns where shipping risks, inconsistent content quality, and uncertain outcomes remain common challenges. Hello IP offers a more efficient alternative. After brands upload content to the platform, creators can select tasks that match their style, audience, and interests, then distribute that content through their own channels. This model helps brands gain more localized and authentic exposure while allowing creators to earn performance-based rewards. To support faster market expansion, Hello IP has developed its core distribution system, Viral Engine, which combines creator distribution, influencer collaboration, advertising support, and cross-market strategies. The platform is currently active in mature TikTok e-commerce markets across Southeast Asia, the United Kingdom, and the United States, with content able to reach targeted creator communities in as little as 24 hours. For creators, Hello IP provides access to daily brand campaigns across categories such as beauty, mobile apps, e-commerce, and gaming. By lowering collaboration barriers and simplifying campaign participation, the platform helps creators unlock more stable income opportunities and build long-term commercial value. Mao Jianfeng, Founder of Hello IP, said, “In today’s creator economy, brands need content distribution models that are more efficient, scalable, and closely connected to local markets. Hello IP aims to build a smoother connection between brands and creators so that both sides can grow together.” As digital marketing enters a new phase, Hello IP’s connector model is creating a more efficient and inclusive path forward for the content ecosystem. About Hello IP Hello IP is one of ET CUBE’s core business pillars in the creator economy, focused on content distribution for social and interest-based e-commerce. Headquartered in Singapore, the platform connects brand content with local creator networks to help brands achieve faster, more authentic distribution and stronger conversion opportunities across key international markets. Media Contact Brand Name: Hello IP Website: https://www.helloipmcn.com

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients. The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance. More information about Desidustat Tablets and Renal Anaemia As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders. There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia. Desidustat Tablets have been approved for marketing in India. CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020. The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6 2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015 3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025) 4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012 CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order. As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients. The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026). Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster. As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2]. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval. The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. China Insights Consultancy’s industrial report 2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739. 3. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 4. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 11, 2026 – (SeaPRwire) – HYVE Promo today announced the launch of its AI-enabled print-on-demand platform designed to modernize Asia-Pacific’s corporate gifting and branded merchandise industry. While e-commerce in Asia has produced multi-billion-dollar unicorns, the region’s corporate gifting supply chain remains largely manual — dependent on spreadsheets, fragmented factory coordination, and week-long quote cycles. HYVE enters the market as a technology-first infrastructure platform built to streamline customization, printing, and cross-border fulfillment at scale. HYVE positions itself as the corporate gifting equivalent of Asia’s major e-commerce platforms — purpose-built for businesses that need fast, reliable, and compliant branded merchandise delivered across multiple markets. “Asia built some of the world’s largest e-commerce engines,” said Tim Ngiam, General Manager of HYVE. “But the corporate merchandise industry hasn’t kept pace. We built HYVE to bring platform thinking, AI-driven workflows, and print-on-demand efficiency to a sector still operating like it’s 2005.” AI-Driven Merch Infrastructure HYVE combines: AI-assisted artwork processing and print optimization Real-time production routing across decoration technologies Automated order batching for small and mid-sized runs Cross-border logistics orchestration for APAC distribution The platform integrates directly with HYVE’s high-capacity production hub in Ningbo, China, capable of processing approximately 500 orders daily. Small-batch corporate orders can ship in as little as 72 hours, serving markets including Singapore, Japan, Korea, India, Southeast Asia, and Greater China. Rather than operating as a marketplace aggregator, HYVE controls the full print-to-ship workflow — reducing supplier handoffs and production errors. Targeting a Rapidly Digitizing Market The global promotional products market is projected to reach US$37 billion by 2033, while Asia-Pacific corporate gifting is expected to exceed US$400 billion within the same timeframe. More than 40% of buyers now expect to manage merchandise orders digitally — from proofing to tracking to fulfillment. HYVE aims to become what its founders call “Asia’s largest merch engine” — a centralized infrastructure layer for corporate gifting across the region. “Marketers and procurement teams want the same simplicity they get when ordering consumer products online,” said Ethan Ung, Co-Founder and Chief Commercial Officer. “They don’t want to manage factories, chase quotes, or coordinate customs. They want speed, visibility, and certainty. That’s what a platform should provide.” Built for Enterprise and Regional Scale HYVE focuses initially on APAC enterprise buyers and distributors, offering: On-demand production Regional multi-country fulfillment Compliance-ready manufacturing standards Rapid turnaround for campaign-driven activations The company plans to expand product categories, introduce deeper AI automation across artwork and routing, and integrate with marketing and e-commerce ecosystems used by enterprise teams. About HYVE Promo HYVE Promo is a Singapore-based technology platform modernizing corporate gifting across Asia-Pacific. Backed by the founders of BrandCharger and Headwind Group, HYVE operates a vertically integrated print and fulfillment engine designed to bring AI-driven efficiency, transparency, and scalability to branded merchandise distribution. For more information, visit: https://hyve.promo Media Contact Ming Yi Lim, Marketing Manager HYVE Promo Pte Ltd mingyi.lim@hyve.promo

SINGAPORE – March 09, 2026 – (SeaPRwire) – AI Labs, an AI-driven crypto trading technology company backed by Academic Labs, announced the launch of an AI-assisted platform designed to help cryptocurrency traders analyze market data and respond more efficiently to changing market conditions. As automated tools and algorithmic strategies become more common in global digital asset markets, the platform integrates visual analysis, narrative data monitoring, and automated trade execution features intended to support more structured and data-driven trading decisions. The fastest traders in today’s crypto markets may not always be humans. As digital asset markets increasingly incorporate automation, many traders now rely on algorithmic systems that can monitor markets continuously and react to signals with minimal delay. A crypto project called AI Labs (ticker: AIX) is building an AI-enabled platform that combines visual reasoning, narrative intelligence, and automated execution to help users interpret market data and respond to signals more efficiently than traditional manual analysis alone. “Markets are entering an era where the use of artificial intelligence is becoming more common in trading strategies,” said Kingston Kwek, owner of AI Labs. “Our goal is to make analytical tools that are often used by institutional trading teams more accessible to a wider group of crypto traders.” At the center of AI Labs’ platform is a visual reasoning engine that analyzes charts not simply as static images, but as evolving market structures. Using computer vision and multimodal AI techniques, the system can identify potential liquidity zones, resistance levels, and broader market patterns within short timeframes. Alongside this, AI Labs has developed a narrative intelligence layer that scans information across the crypto ecosystem. This includes movements associated with large crypto wallets, developer updates, and shifts in online sentiment—signals that traders often monitor when assessing possible market trends. Instead of only placing individual buy or sell orders, traders can define broader trading parameters using the AI system. The platform can then execute trades automatically based on predefined conditions, such as capital inflows, volatility changes, or funding-rate shifts. The objective is to help reduce emotional decision-making and allow traders to stay aligned with their strategies while automated systems monitor market activity continuously. AI Labs’ platform is currently onboarding new users, with reported monthly trading activity exceeding $1 billion across the platform. Media Contact Brand: AI Labs (Backed by Academic Labs) Contact: Media team Email: ryan@academic-labs.org Website: https://academic-labs.org

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 05, 2026 – (SeaPRwire) – Core Concepts Physio, one of Singapore’s leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain. Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved. To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked. A Smarter, More Complete Way to Diagnose Heel Pain Physiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support. The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in: More accurate, holistic diagnoses Fully optimised treatment strategies Fewer flare-ups and recurrences Clearer, consistent guidance for patients Faster and more sustainable outcomes “Many patients struggle because plantar fasciitis isn’t caused by just one issue,” said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. “It’s a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms.” A Case Study Demonstrating Collaborative Success In a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts. A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient’s daily load decreased significantly — allowing physiotherapy progress to continue without setbacks. Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running. “This case reflects what we see frequently,” said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. “Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery.” Making Multidisciplinary Care Accessible Nationwide Through this collaboration, patients with plantar fasciitis now benefit from: Joint physiotherapy–podiatry assessments Aligned clinical decision-making Consistent communication across providers A thorough evaluation of both the cause and consequence of heel pain A fully optimised recovery pathway “Our multidisciplinary team brings together the best of both professions,” said Mr Chng Chye Tuan. “Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands.” About Core Concepts Physiotherapy Core Concepts Physio is one of Singapore’s largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580. About Podiatry Quest Podiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care. Contact Details Organization: Core Concepts Pte Ltd Contact: Clemence Lim Email: marketing@coreconcepts.com.sg Website: https://www.coreconceptsphysio.sg

Base58 Labs Advances Integration of Proprietary BHLE Infrastructure LONDON, United Kingdom – March 04, 2026 – (SeaPRwire) – BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure. BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets. Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture. In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling. “Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.” BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants. With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026. About Base58 Labs Base58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/ Media Contact Base58 Labs PR Team Email: info@base58labs.com BASIS Official Website: https://basis.pro/ Base58 Labs Official Website: https://base58labs.com/

Tashkent, Uzbekistan – March 04, 2026 – (SeaPRwire) – FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium – a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework. Why Uzbekistan – Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter. Asterium’s project is designed to operate fully within this framework. What Was Deployed – FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium’s business model. The core deployment covers three key layers: Banking infrastructure – management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems. Digital asset infrastructure – crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan’s Mirasmanda ledger for HUMO asset support. Compliance and exchange – a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off. The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards – all within a regulated environment. How the Partnership Works – FinHarbor operates as Asterium’s strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion. “This project required deep architectural customization – from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards,” said Ilya Podoynitsyn, CEO of FinHarbor. “The core phase is complete, and we are already scaling the platform with new products and business use cases.” What’s Next – With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform’s functionality to support additional business lines built on the deployed stack. About FinHarbor FinHarbor provides modular technology infrastructure for launching compliant financial products – from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets. Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Email: press@finharbor.com Website: https://www.finharbor.com/

Hong Kong – March 02, 2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026. Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how. Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational. Governing AI in a Fragmented World On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI). The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes. Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third. The problem is not only detection. It is coordination under uncertainty. The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims. Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals. AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure. Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement. The Evidence Dilemma and the 2026 International AI Safety Report On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute. The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare. The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed. The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered. The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability. For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates. From Conversation to Capacity AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate. Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact. About AI Safety Asia AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement. AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up. Social Link LinkedIn: https://www.linkedin.com/company/ai-safety-asia/ Media Contact Brand: AI Safety Asia Contact: Media team Email: contact@aisafety.asia Website: https://www.aisafety.asia

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape. According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge. Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.” The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time. Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music. Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone. This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates. About Dr. Don Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression. Media Contact Dr. Don E: don@drdonmusic.com W: https://drdonmusic.com/

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my

New York, NY – February 01, 2026 – (SeaPRwire) – Recently, the world’s only Pokémon card graded PSA 10 – Pikachu Illustrator – once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment. Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory. The Legendary Status of the World’s Only PSA 10 According to publicly available information, the world’s only PSA 10 “Pikachu Illustrator” card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting. The Industry Significance of Goldin Auctions Although Logan Paul’s acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card’s contemporary circulation and visibility. As one of the world’s most influential high-end collectibles auction platforms, Goldin’s auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market. Netflix Documentary Captures a Cultural Moment Amid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference. Global Participation and TCG.Zone’s Involvement The discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand. Continuing to Follow the Card’s Future Trajectory In post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world’s only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value. The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting. Social Links Twitter: https://x.com/tcgzoneofficial Instagram: https://www.instagram.com/tcgzoneofficial/ Telegram: https://t.me/tcgzoneofficial Media Contact Brand : The Collectors Grid (tcg.zone) Contact: Annie Email: hi@tcg.zone Website: https://www.tcg.zone

SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/